Most searched

Categories // Subject Area // Gynecologic

  • Olaparib made available on the NHS for BRCA-positive ovarian cancer patients

26 Jul 2019 Drug approvals | Gynecologic | Industry and business | News
In this image from a mouse model of ovarian cancer, optically cleared tumor excised from a murine SKOV tumor seeded with CD63+ cells reveals a high-resolution landscape of the three-dimensional tumor-stromal interfaces that comprise the tumor microenvironment (TME). Second harmonic signal (blue) and autofluorescent /GFP signals (green) demonstrates the interplay of collagen II fibrils and vessels generated from angiogenesis. The use of optical tissue clearing has the potential to greatly improve researchers' ability to assess the anatomic, structural, and cellular constituents that govern metastatic colonization in the TME at a single-cell resolution.
Photo credit: NIH NCI Visuals Online

AstraZeneca and MSD (both UK) today announced that Lynparza® (olaparib) is now recommended for use within the Cancer Drugs Fund via the NHS in England  as a treatment option for the BRCA mutation-positive, advanced high-grade epithelial ovarian, fallopian tube or primary peritneal cancer that has responded to first-line platinum-based chemotherapy in adults.

To view the full article, please register now for access

It's completely free

Register

Written ByLouis Gautier, Future Science Group

Updated 31 July, 2019

Related Tags
Drug Approvals,Gynecologic,Industry and Business,Ovarian,

Related articles